Clinical Trials · NCT07843862
A Study of HRS-4729 Injection in Participants With Type 2 Diabetes
- Phase
- Phase 2
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Enrollment
- 240
- Start date
- Oct 2026
- Locations
- 2 sites, China
- Primary endpoint
- Change From Baseline in HbA1c